Repositorio UVigo

Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer

Investigo Repository

Value of serum NEUROG1 methylation for the detection of advanced adenomas and colorectal cancer

Otero Estevez, Olalla; Gallardo Gomez, María; Páez de la Cadena Tortosa, María; Rodríguez Berrocal, Francisco Javier; Cubiella, Joaquín; Hernandez Ramirez, Vicent; García-Nimo, Laura; De Chiara Prada, Loretta
 
DATE : 2020-06-28
UNIVERSAL IDENTIFIER : http://hdl.handle.net/11093/1745
UNESCO SUBJECT : 3201.01 Oncología ; 3210 Medicina Preventiva ; 3212 Salud Publica
DOCUMENT TYPE : article

ABSTRACT :

Aberrant DNA methylation detected in liquid biopsies is a promising approach for colorectal cancer (CRC) detection, including premalignant advanced adenomas (AA). We evaluated the diagnostic capability of serum NEUROG1 methylation for the detection of AA and CRC. A CpG island in NEUROG1 promoter was assessed by bisulfite pyrosequencing in a case-control cohort to select optimal CpGs. Selected sites were evaluated through a nested methylation-specific qPCR custom assay in a screening cohort of 504 asymptomatic family-risk individuals. Individuals with no colorectal findings and benign pathologies showed low serum NEUROG1 methylation, similar to non-advanced adenomas. Contrarily, individuals bearing AA or CRC (advanced neoplasia—AN), exhibited increased NEUROG1 methylation. Using >1.3518% as NEUROG1 cut-off (90.60% specificity), 33.33% of AN and 32.08% of AA were identified, detecting 50% CRC cases. Nonetheless, the combination of NEUROG1 with fecal immunochemical test (FIT), together with age and gender through a multivariate logistic regression resulted in an AUC = 0.810 for AN, ... [+]
Aberrant DNA methylation detected in liquid biopsies is a promising approach for colorectal cancer (CRC) detection, including premalignant advanced adenomas (AA). We evaluated the diagnostic capability of serum NEUROG1 methylation for the detection of AA and CRC. A CpG island in NEUROG1 promoter was assessed by bisulfite pyrosequencing in a case-control cohort to select optimal CpGs. Selected sites were evaluated through a nested methylation-specific qPCR custom assay in a screening cohort of 504 asymptomatic family-risk individuals. Individuals with no colorectal findings and benign pathologies showed low serum NEUROG1 methylation, similar to non-advanced adenomas. Contrarily, individuals bearing AA or CRC (advanced neoplasia—AN), exhibited increased NEUROG1 methylation. Using >1.3518% as NEUROG1 cut-off (90.60% specificity), 33.33% of AN and 32.08% of AA were identified, detecting 50% CRC cases. Nonetheless, the combination of NEUROG1 with fecal immunochemical test (FIT), together with age and gender through a multivariate logistic regression resulted in an AUC = 0.810 for AN, and 0.796 for AA, detecting all cancer cases and 35–47% AA (specificity 98–95%). The combination of NEUROG1 methylation with FIT, age and gender demonstrated a convenient performance for the detection of CRC and AA, providing a valuable tool for CRC screening programs in asymptomatic individuals. [-]

Show full item record



Files in this item

Creative Commons Attribution
(CC BY) license Except where otherwise noted, this item's license is described as Creative Commons Attribution (CC BY) license
2013 Universidade de Vigo, Todos los derechos reservados
Calidad So9001